- Home
- NRIX vs GAM Comparison
NRIX vs GAM Comparison
Compare NRIX & GAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRIX | GAM |
|---|---|---|
| Founded | 2009 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | NRIX | GAM |
|---|---|---|
| Price | $14.53 | $63.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $30.50 | N/A |
| AVG Volume (30 Days) | ★ 961.1K | 27.7K |
| Earning Date | 04-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 5.74% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 11.67 |
| Revenue | ★ $76,987,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $48.05 | N/A |
| P/E Ratio | ★ N/A | $5.47 |
| Revenue Growth | ★ 99.31 | N/A |
| 52 Week Low | $8.20 | $53.78 |
| 52 Week High | $22.50 | $66.18 |
Technical Indicators
Market Signals| Indicator | NRIX | GAM |
|---|---|---|
| Relative Strength Index (RSI) | 32.11 | 41.29 |
| Support Level | $11.67 | $62.41 |
| Resistance Level | $17.06 | $64.41 |
| Average True Range (ATR) | 0.90 | 0.83 |
| MACD | -0.26 | -0.16 |
| Stochastic Oscillator | 3.88 | 3.47 |
Price Performance
Historical ComparisonAbout NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
About GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations. The company invests principally in common stocks believed by management to have growth potential.